1,367
Views
23
CrossRef citations to date
0
Altmetric
Case Report

Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab

, , , , , , , , , & show all
Pages 134-137 | Received 05 Sep 2012, Accepted 14 Feb 2013, Published online: 18 Feb 2014

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (6)

Bénédict Fallet & Ulrich A. Walker. (2020) Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies. Expert Review of Clinical Pharmacology 13:11, pages 1203-1218.
Read now
Yoshihito Shima. (2019) The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis. Modern Rheumatology 29:2, pages 294-301.
Read now
Yoshihito Shima, Yasushi Kawaguchi & Masataka Kuwana. (2019) Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Modern Rheumatology 29:1, pages 134-139.
Read now
Christina G. Katsiari, Theodora Simopoulou, Ioannis Alexiou & Lazaros I. Sakkas. (2018) Immunotherapy of systemic sclerosis. Human Vaccines & Immunotherapeutics 14:11, pages 2559-2567.
Read now
Lazaros I Sakkas. (2016) Spotlight on tocilizumab and its potential in the treatment of systemic sclerosis. Drug Design, Development and Therapy 10, pages 2723-2728.
Read now
Özgül Muştu Koryürek & Göknur Kalkan. (2016) A new alternative therapy in dermatology: tocilizumab. Cutaneous and Ocular Toxicology 35:2, pages 145-152.
Read now

Articles from other publishers (17)

Martin Iglesias, Iván Torre-Villalvazo, Patricia Butrón-Gandarillas, Tatiana S. Rodríguez-Reyna, Erik A. Torre-Anaya, Martha Guevara-Cruz, Miguel A. Flores-Cháirez, Diana B. López-Contreras, Joana Y. López-Sánchez, Ángel J. Ruiz-Betanzos, Ana L. Méndez López, Carolina Rubio-Gutierrez, Fernando Téllez-Pallares & Fabian Nario-Chaidez. (2023) Adipose derived stromal vascular fraction and fat graft for treating the hands of patients with systemic sclerosis. A randomized clinical trial. PLOS ONE 18:8, pages e0289594.
Crossref
Theodoros-Ioannis Papadimitriou, Arjan van Caam, Peter M. van der Kraan & Rogier M. Thurlings. (2022) Therapeutic Options for Systemic Sclerosis: Current and Future Perspectives in Tackling Immune-Mediated Fibrosis. Biomedicines 10:2, pages 316.
Crossref
Gerarda Cappuccio, Martina Caiazza, Alessandro Roca, Daniela Melis, Antonella Iuliano, Gabor Matyas, Marta Rubino, Giuseppe Limongelli & Nicola Brunetti‐Pierri. (2020) A pilot clinical trial with losartan in Myhre syndrome. American Journal of Medical Genetics Part A 185:3, pages 702-709.
Crossref
Xinh-Xinh Nguyen, Tetsuya Nishimoto, Takahisa Takihara, Logan Mlakar, Amy D. Bradshaw & Carol Feghali-Bostwick. (2021) Lysyl oxidase directly contributes to extracellular matrix production and fibrosis in systemic sclerosis. American Journal of Physiology-Lung Cellular and Molecular Physiology 320:1, pages L29-L40.
Crossref
Hiroki Wakabayashi, Hitoshi Kino, Makoto Kondo, Keiichi Yamanaka, Masahiro Hasegawa & Akihiro Sudo. (2019) Efficacy of subcutaneous tocilizumab in patients with rheumatoid arthritis and systemic sclerosis overlap syndrome: a report of two cases and review of the literature. BMC Rheumatology 3:1.
Crossref
Brigit Kersten & Madelon Vonk. (2019) Treatment of Diffuse Cutaneous Systemic Sclerosis with Biologics, Small Molecules and Stem Cell Transplantation: What Is the Evidence to Date?. Current Treatment Options in Rheumatology 5:2, pages 104-114.
Crossref
Masashi Narazaki & Tadamitsu Kishimoto. (2018) The Two-Faced Cytokine IL-6 in Host Defense and Diseases. International Journal of Molecular Sciences 19:11, pages 3528.
Crossref
A. Fernández-Codina, J. Fernández-Fernández & A. Fernández-Pantiga. (2018) Use of tocilizumab in systemic sclerosis: A brief literature review. Revista Clínica Española (English Edition) 218:6, pages 298-304.
Crossref
A. Fernández-Codina, J. Fernández-Fernández & A. Fernández-Pantiga. (2018) Utilización de tocilizumab en la esclerosis sistémica: breve revisión de la literatura. Revista Clínica Española 218:6, pages 298-304.
Crossref
Galia Zacay & Yair Levy. (2018) Outcomes of patients with systemic sclerosis treated with tocilizumab: Case series and review of the literature. Best Practice & Research Clinical Rheumatology 32:4, pages 563-571.
Crossref
Masutaka Furue, Chikage Mitoma, Hiroki Mitoma, Gaku Tsuji, Takahito Chiba, Takeshi Nakahara, Hiroshi Uchi & Takafumi Kadono. (2017) Pathogenesis of systemic sclerosis—current concept and emerging treatments. Immunologic Research 65:4, pages 790-797.
Crossref
A.M. Saracino, C.P. Denton & C.H. Orteu. (2017) The molecular pathogenesis of morphoea: from genetics to future treatment targets. British Journal of Dermatology 177:1, pages 34-46.
Crossref
Dinesh Khanna, Angelika Jahreis & Daniel E. Furst. (2017) Tocilizumab Treatment of Patients with Systemic Sclerosis: Clinical Data. Journal of Scleroderma and Related Disorders 2:2_suppl, pages S29-S35.
Crossref
Yasushi Kawaguchi. (2017) Contribution of Interleukin-6 to the Pathogenesis of Systemic Sclerosis. Journal of Scleroderma and Related Disorders 2:2_suppl, pages S6-S12.
Crossref
Catherine H. Orteu & Christopher P. Denton. 2016. Rook's Textbook of Dermatology, Ninth Edition. Rook's Textbook of Dermatology, Ninth Edition 1 28 .
Kouki Nakamura, Yoshihide Asano, Takashi Taniguchi, Shun Minatsuki, Toshiro Inaba, Hisataka Maki, Masaru Hatano, Takashi Yamashita, Ryosuke Saigusa, Yohei Ichimura, Takehiro Takahashi, Tetsuo Toyama, Ayumi Yoshizaki, Tomomitsu Miyagaki, Makoto Sugaya & Shinichi Sato. (2016) Serum levels of interleukin‐18‐binding protein isoform a: Clinical association with inflammation and pulmonary hypertension in systemic sclerosis. The Journal of Dermatology 43:8, pages 912-918.
Crossref
Yoshihito Shima. 2016. Systemic Sclerosis. Systemic Sclerosis 103 115 .